echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Recently, medical companies have been taking frequent actions! Busy with acquisition, construction of R&D bases...

    Recently, medical companies have been taking frequent actions! Busy with acquisition, construction of R&D bases...

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the medical industry has become a well-deserved "star industry"
    .
    While frequently obtaining capital to increase weight, related enterprises are also becoming more and more frequent in acquisitions and
    the construction of R&D bases in order to enhance their competitiveness.

     
    Canon Medical invested USD 300 million to strengthen its imaging business
     
    On January 4, 2023, it was learned that Canon Medical plans to spend US$300 million to open a new subsidiary, Canon Healthcare USA, in the United States, aiming to strengthen its imaging business and focus sales and investments on the US market
    .
    Canon Medical aims to strengthen its commercial competitiveness in various areas of the medical industry, including imaging diagnostic technologies such as CT, MR and ultrasound, as well as core component business, including X-ray tubes, detectors and key MR components
    .

     
    It is understood that the new company will be established in January 2023, is expected to hire 20 employees in the early stage, and is expected to be located in Cleveland because it is close to the large medical market on the east coast and the Midwest of the United States, and it is also the headquarters of Quality Electrodynamics, a MR module developer acquired by Canon Group in 2019, and Quality Electrodynamics will also be included in the new company
    .
    Sales of Canon's CT and other diagnostic imaging systems in the U.
    S.
    market are expected to double by 2025
    .

     
    Fujifilm expands digital pathology business
     
    Recently, Fujifilm Group announced the acquisition of Inspirata's digital pathology business, which is expected to close in early 2023
    .
    It is reported that as early as 2020, Fujifilm and Inspirata have established a partnership, Fujifilm can exclusively sell and service Inspirata's digital pathology workflow software worldwide, including the United Kingdom, Italy, Spain, Portugal, Belgium, the Netherlands and Luxembourg and other countries
    .

     
    Fujifilm's acquisition includes Inspirata's Dynamyx digital pathology technology, which has received regulatory approvals
    in the United States, Canada, Europe and the United Kingdom.
    Upon completion of the acquisition, Dynamyx will be included in
    Fujifilm's Synapse Enterprise Imaging portfolio.
    It is reported that Synapse Enterprise Imaging is a medical IT system launched by Fujifilm in 1999, integrating imaging, data access and workflow
    .

     
    The second phase of the United Imaging Medical Production R&D Base project was started
     
    On December 5th, the groundbreaking ceremony of the second phase of the general contracting project of United Imaging Medical Production and R&D Base was held
    in Shanghai.
    The project is located in Plot 05-06 and Plot 01-02 of Jiading Industrial Zone, Shanghai, with a total construction area of about 273,000 square meters, and is a demonstration base
    for the medical industrialization of United Imaging Imaging with Plot 02-02, which started construction in January 2022.

     
    This demonstration base will be built into a smart park integrating technology research and development, intelligent manufacturing, international exchange and training, global brand display, life services, central park and other functions, which can accommodate 8,000 to 10,000 people
    .
    On January 3, 2023, United Imaging Medical also issued an announcement on the implementation progress of some fundraising projects, disclosing the progress of
    the fundraising investment projects.

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.